External validation of the Heidenreich criteria for patient selection for unilateral or bilateral retroperitoneal lymph node dissection for post-chemotherapy residual masses of testicular cancer
- 20 January 2014
- journal article
- Published by Springer Nature in World Journal of Urology
- Vol. 32 (6) , 1573-1578
Abstract
To validate the Heidenreich criteria for patient selection for unilateral retroperitoneal lymph node dissection (RPLND) for residual masses after chemotherapy for nonseminomatous germ cell tumor (NSGCT). For validation, the data of 59 patients who underwent RPLND for residual masses of NSGCT were used. Of these patients, 23 (39 %) qualified for a modified RPLND, the others had an indication for a bilateral dissection. Results from histopathology after RPLND and follow-up data for relapse inside or outside the zone of the resection template were considered for validation. In the study cohort, median age at time of RPLND was 31 years. The 2-year disease-free survival was 90 and 96 % for the bilateral and the unilateral RPLND patients, respectively. Overall, 8 (14 %) relapses were observed after a median follow-up of 54 month. Of these, 6 were outside of the resection field and 2 were in-field. Of the 23 patients with indication for a modified RPLND, 1 patient relapsed in the contralateral testis and 1 inside the modified RPLND template. No relapse was observed outside the modified RPLND field and inside the untouched contralateral RPLND field. The Heidenreich criteria did therefore not misclassify a single patient. The Heidenreich criteria for the selection of candidates for unilateral RPLND for residual masses after chemotherapy allow a highly reliable selection of patients. The application of the Heidenreich criteria can help to reduce comorbidity and invasiveness of RPLND.Keywords
This publication has 24 references indexed in Scilit:
- EAU Guidelines on Testicular Cancer: 2011 UpdateEuropean Urology, 2011
- Long‐term oncological outcome after post‐chemotherapy retroperitoneal lymph node dissection in men with metastatic nonseminomatous germ cell tumourBJU International, 2010
- Management of Disseminated Nonseminomatous Germ Cell Tumors With Risk-Based Chemotherapy Followed by Response-Guided Postchemotherapy SurgeryJournal of Clinical Oncology, 2010
- Evidence-based pragmatic guidelines for the follow-up of testicular cancer: optimising the detection of relapseBritish Journal of Cancer, 2008
- Is full bilateral retroperitoneal lymph node dissection always necessary for postchemotherapy residual tumor?Cancer, 2007
- Late Relapses of Germ Cell Malignancies: Incidence, Management, and PrognosisJournal of Clinical Oncology, 2006
- Incidence of Late-Relapse Germ Cell Tumor and Outcome to Salvage ChemotherapyJournal of Clinical Oncology, 2005
- Prediction of Necrosis After Chemotherapy of Advanced Germ Cell Tumors: Results of a Prospective Multicenter Trial of the German Testicular Cancer Study GroupJournal of Urology, 2004
- Complications of Post-Chemotherapy Retroperitoneal Lymph Node Dissection for Testis CancerJournal of Urology, 2004
- Retroperitoneal lymphadenectomy for post‐chemotherapy residual masses: is a modified dissection and resection of residual masses sufficient?British Journal of Urology, 1998